OncLive TV

Daniel J. George, MD, discusses the use of niraparib for patients with metastatic castration-resistant prostate cancer harboring BRCA and ATM mutations.

Joshua K. Sabari, MD, discusses the importance of timely testing for uncommon mutations in non–small cell lung cancer.

Nicholas C. Rohs, MD, discusses databases of uncommon mutations in non–small cell lung cancer

Akash Mukherjee, MD, discusses the implications of the FDA approval of lisocabtagene maraleucel in large B-cell lymphoma.

John Moroney, MD, discusses the evaluation of COM701 plus BMS-986207 and nivolumab in platinum-resistant ovarian cancer.

Oladapo Yeku, MD, PhD, FACP, discusses the evaluation of COM701 with nivolumab in patients with platinum-resistant epithelial ovarian cancer.

William Jacot, MD, PhD, discusses updated efficacy and safety results from the phase 2 AMALEE trial.

Sara A. Hurvitz, MD, discusses sequencing therapeutic options for patients with HER2-positive breast cancer. 

Jason Romancik, MD, discusses efforts to maximize the efficacy of CAR T-cell therapy in non-Hodgkin lymphoma.

Sandra P. Susanibar-Adaniya, MD, discusses 2 key trials in multiple myeloma that improved the treatment landscape for transplant-eligible and ineligible patients.

Aditya Bardia, MD, MPH, discusses the use of elacestrant in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer.

Sara A. Hurvitz, MD, discusses updated survival data with fam-trastuzumab deruxtecan-nxki in HER2-positive, unresectable/metastatic breast cancer.

Yara Abdou, MD, discusses racial disparities in breast cancer outcomes in patients enrolled to the phase 3 RxPONDER trial.

Ian Krop, MD, PhD, discusses findings from the phase 3 DESTINY-Breast02 trial in patients with HER2-positive metastatic breast cancer.

Sapna Patel, MD, discusses the evaluation of adjuvant nivolumab plus ipilimumab in stage IV metastatic melanoma with no evidence of disease.

Manish Patel, MD, DO, discusses choosing a chemoimmunotherapy regimen for patients with advanced, metastatic non–small cell lung cancer.

Rodney Rocconi, MD, discusses the impact of the phase 3 SORAYA trial in folate receptor alpha–positive ovarian cancer.

Mojun Zhu, MD, discusses key findings from the phase 3 TOPAZ-1 trial in patients with biliary tract cancer.

Suneel Kamath, MD, discusses the prevalence of FGFR2 fusions or rearrangements in cholangiocarcinoma.

Brian Andrew Jonas, MD, PhD, discusses the exploration of uproleselan plus standard therapies in acute myeloid leukemia.

Lionel Kankeu Fonkoua, MD, discusses key considerations when selecting a treatment regimen for patients with hepatocellular carcinoma.

Joanna M. Rhodes, MD, discusses evaluating the unmet needs of elderly patients in CLL.

Gary J. Schiller, MD, discusses the benefits and challenges associated with JAK-directed therapies in the treatment of patients with myelofibrosis.

Stephen V. Liu, MD, discusses the expanding exploration of antibody-drug conjugates in non–small cell lung cancer.

Matthew P. Goetz, MD, discusses the impact of the phase 3 PALOMA-2 trial in estrogen receptor–positive/HER2-negative advanced breast cancer.

Sebastian C. Schmid, MD, discusses the future of the phase 2 RACE IT trial in urothelial carcinoma.

Anna C. Pavlick, DO, discusses the sequencing of immunotherapy vs targeted therapy in BRAF-mutated melanoma.

Alison K. Conlin, MD, discusses the inception of the HER2-low breast cancer treatment landscape.

Sam Klempner, MD, discusses the investigation of adagrasib in KRAS G12C–mutated metastatic colorectal cancer.

Sandra P. Susanibar-Adaniya, MD, discusses the current standard of care for patients with newly diagnosed multiple myeloma.